前列地尔注射液联合吡格列酮治疗糖尿病肾病的临床效果分析

To Observe the Clinical Effect of Alprostadil Injection Combined with Pioglitazone for the Treatment of Diabetic Nephropathy

目的分析研究糖尿病肾病患者通过前列地尔注射液联合吡格列酮进行治疗的方法以及治疗效果,为临床提供有力的依据。方法回顾性分析该院在2014年11月—2015年11月所收治的糖尿病肾病患者资料120例,将所选取的120例患者依照其入院顺序分为3组,平均每组40例,A组患者通过静脉注射前列地尔注射液进行治疗,B组患者通过口服吡格列酮进行治疗,C组患者通过静脉注射前列地尔注射液联合吡格列酮进行治疗,3组患者全部治疗一个疗程,统计3组患者的尿蛋白和肾功能各项指标,将所得结果进行统计学分析。结果 3组患者治疗之后的血尿素氮、血肌酐、血清同型半胱氨酸、24 h尿蛋白量、β2微球蛋白以及尿微量清蛋白水平分别为显著降低,和治疗之前对比存在统计学意义(P<0.05);C组患者治疗之后下降程度更为显著,分别为:(3.39±1.19)mmol/L、(44.59±10.79)μmol/L、(6.22±2.53)μmol/L、(106.11±47.05)mg、(2.06±0.33)mg/L、(52.62±8.36)μg/L,与上述两组比较存在统计学意义(P<0.05);三组患者治疗之后的血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇以及高密度脂蛋白胆固醇水平明显下降,与治疗之前存在统计学意义(P<0.05);C组患者治疗之后下降程度更为显著,分别为:(3.15±1.01)、(1.37±0.48)、(2.06±1.03)、(1.63±0.41)mmol/L,与上述两组比较差异有统计学意义(P<0.05)。结论针对糖尿病肾病患者给予其前列地尔注射液联合吡格列酮治疗效果显著,应该在临床中大力推广使用。

Objective Analysis of patients with diabetic nephropathy by alprostadil injection combined with pioglitazone for methods of treatment and curative effect, provide strong basis for clinical. Methods A retrospective analysis of our hospital in November 2014 to November 2015 were diabetic nephropathy patients with 120 cases, the selected 120 patients were in accordance with the order of admission divided into three groups, average, 40 cases in each group, patients in group A and group B by intravenous injection of alprostadil injection treatment, patients in group B were through the oral administration of pioglitazone treatment, patients in group C by intravenous injection of alprostadil injection combined with pioglitazone treatment, all three groups of patients with treatment of a course of treatment, the statistics of the three groups of patients with urinary protein and renal function indexes. The results were analyzed. The Results The blood urea nitrogen, serum creatinine, serum homocysteine, after treatment in three groups of 24 hours urine protein, beta 2 microglobulin and urinary albumin levels were significantly decreased, and there were statistically significant contrast before treatment(P < 0.05); after treatment in group C were more significantly decreased, respectively.(3.39±1.19) mmol/L,(44.59±10.79) mmol/L(6.22±2.53) mol/L,(106.11±47.05)mg,(2.06±0.33) mg/L,(52.62±8.36) μg/L, compared with the two groups had statistical significance(P < 0.05); after treatment in three groups of serum total cholesterol, triglyceride, low density lipoprotein cholesterol and high density lipoprotein cholesterol level decreased significantly, and before treatment had statistical significance(P < 0.05); after treatment in group C were more significantly decreased, respectively:(3.15 ±1.01) mmol/L,(1.37 ± 0.48) mmol/L,(2.06 ±1.03) mmol/L,(1.63 ±0.41) mmol/L, and the above two groups were statistically significant(P < 0.05). Conclusion For patients with diabetic nephropathy(DN) given the alprostadil injection combined with pioglitazone treatment effect is significant, it should be popularized in clinical.